Trademark: 90424617
Status Date
Tuesday, June 7, 2022
Registration Number
6750023
Registration Date
Tuesday, June 7, 2022
Filing Date
Tuesday, December 29, 2020
Published for Opposition
Tuesday, February 15, 2022
5 Pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; anti-cancer drugs; anti-cancer preparations; anti-cancer preparations of plant origin; anti-cancer preparations of chemical origin; compounds for treating cancer; tumor suppressing agents; immunostimulants; medicine for the treatment of cancer; diagnostic reagents for medical laboratory use
45 Licensing of intellectual property rights; licensing of industrial property rights
44 Medical screening; medical monitoring, testing, inspection and analysis services; medical services relating to the diagnosis and treatment of cancerous diseases; pharmaceutical advisory services; medical laboratory analysis services relating to the treatment of persons; medical laboratory analysis services relating to the diagnosis and treatment of cancerous diseases; providing cancer screening services; medical analysis services for cancer diagnosis and prognosis; RNA or DNA analysis for cancer diagnosis and prognosis; medical services in the field of oncology, immunology and immuno-oncology; providing advice relating to oncology, immunology and immuno-oncology; providing on-line information relating to oncology, immunology and immuno-oncology
42 Development of platform technology, namely, cancer immunotherapy platforms for manufacturing therapeutics; research and development of pharmaceuticals in the fields of oncology, immunology and immuno-oncology; research and development of pharmaceuticals for the treatment of cancer and oncological conditions; research and development in the field of cancer therapeutics, oncology, nanoparticles, and targeted therapies; research and development in the field of recombinant proteins and antibodies for therapeutic and prophylactic use; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new therapeutic proteins and antibodies; development of pharmaceuticals, pharmaceutical ingredients, and antibodies; scientific study and research in the field of developing personal scientific treatment strategies for patients with diagnosed cancer; pharmaceutical services, namely, developing tumor targeting platform technologies; scientific research in the nature of scientific collection of specific molecular and genomic data for analytical and clinical purposes, for the treatment of cancer and other diseases and disorders and for individuals' responses to drug treatments; providing medical and scientific research information in the field of pharmaceuticals and clinical trials in the fields of oncology, immunology and immuno-oncology; pharmaceutical product development and evaluation services; pharmaceutical research and development; technical research in the field of pharmaceutical studies; conducting early evaluations in the field of new pharmaceuticals; conducting clinical trials for others in the field of pharmaceuticals for the treatment and prevention of cancer; consulting services in the fields of biotechnology and pharmaceutical research; consulting services for others in the field of design, planning, and implementation of clinical trials; providing medical and scientific research information in the field of pharmaceuticals and clinical trials
Jun 7, 2022
Notice Of Registration Confirmation Emailed
Jun 7, 2022
Registered-Principal Register
Apr 29, 2022
Electronic Record Review Complete
Apr 1, 2022
On Hold - Electronic Record Review Required
Feb 15, 2022
Official Gazette Publication Confirmation E-Mailed
Feb 15, 2022
Published For Opposition
Jan 26, 2022
Notification Of Notice Of Publication E-Mailed
Jan 10, 2022
Law Office Publication Review Completed
Jan 10, 2022
Approved For Pub - Principal Register
Jan 10, 2022
Examiner's Amendment Entered
Jan 10, 2022
Notification Of Examiners Amendment E-Mailed
Jan 10, 2022
Examiners Amendment E-Mailed
Jan 10, 2022
Examiners Amendment -Written
Dec 28, 2021
Teas/Email Correspondence Entered
Dec 28, 2021
Correspondence Received In Law Office
Dec 23, 2021
Assigned To Lie
Dec 21, 2021
Teas Response To Office Action Received
Jun 28, 2021
Notification Of Non-Final Action E-Mailed
Jun 28, 2021
Non-Final Action E-Mailed
Jun 28, 2021
Non-Final Action Written
Jun 28, 2021
Assigned To Examiner
Mar 20, 2021
New Application Office Supplied Data Entered In Tram
Jan 1, 2021
New Application Entered In Tram
Trademark Alertz updated from USPTO on 2030-01-24
